Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

Myositis

Myositis

Get ready for ACR Convergence 2020

5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

Visit the conference hub

26-02-2020 | Glucocorticoids | Highlight | News

Metformin could mitigate glucocorticoid-related complications

Findings from a proof-of-concept phase 2 study suggest that treatment with the antidiabetes drug metformin could help minimize some metabolic complications and improve clinical outcomes for patients taking systemic glucocorticoid therapy.

Metformin could mitigate glucocorticoid-related complications

Findings from a proof-of-concept phase 2 study suggest that treatment with the antidiabetes drug metformin could help minimize some metabolic complications and improve clinical outcomes for patients taking systemic glucocorticoid therapy.

Metformin could mitigate glucocorticoid-related complications

Do myositis-specific antibodies have an impact on the treatment of idiopathic inflammatory myopathies?

Latika Gupta and Rohit Aggarwal evaluate the use of myositis-specific antibodies in the classification and management of this disease.

Do myositis-specific antibodies have an impact on the treatment of idiopathic inflammatory myopathies?

15-01-2020 | Myositis | Editorial | Article

Do myositis-specific antibodies have an impact on the treatment of idiopathic inflammatory myopathies?

Latika Gupta and Rohit Aggarwal evaluate the use of myositis-specific antibodies in the classification and management of this disease.

01-11-2019 | Infection | News

Burden of opportunistic infections high for patients with polymyositis, dermatomyositis

A 13-year cohort study indicates that systemic rheumatic diseases are associated with an increased incidence of opportunistic infections, and suggests that patients with polymyositis or dermatomyositis have the highest rates.

14-12-2018 | Pediatric | Article

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Jung JY et al. Pediatr Rheumatol 2018; 16: 79. doi: 10.1186/s12969-018-0296-z

20-11-2018 | Myositis | Article

Long-term follow-up of autologous hematopoietic stem cell transplantation for refractory juvenile dermatomyositis: A case-series study

Zhu J et al. Pediatr Rheumatol 2018; 16: 72. doi: 10.1186/s12969-018-0284-3

Rheumatic immune-related adverse events from cancer immunotherapy

In this review, mechanisms of action of checkpoint inhibitors and how they might cause rheumatic immune-related adverse events are described [read more].
Calabrese LH, Calabrese C, Cappelli LC. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0074-9

Rheumatic immune-related adverse events from cancer immunotherapy

15-09-2018 | Myositis | Review | Article

Current treatment for myositis

Barsotti S, Lundberg IE. Curr Treat Options in Rheum 2018. doi: 10.1007/s40674-018-0106-2

31-08-2018 | Immune checkpoint inhibitor-induced rheumatic disease | Review | Article

Rheumatic immune-related adverse events from cancer immunotherapy

Calabrese LH, Calabrese C, Cappelli LC. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0074-9

03-08-2018 | Pathophysiology | Review | Article

S100 proteins in rheumatic diseases

Austermann J, Spiekermann C, Roth J. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0058-9

16-07-2018 | Dermatomyositis | Article

Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis

Mamyrova G et al. Rheumatology (Oxford) 2018. doi: 10.1093/rheumatology/key190

11-07-2018 | Pediatric | Review | Article

Pediatric Rheumatology Collaborative Study Group: Over four decades of pivotal clinical drug research in pediatric rheumatology

Brunner HI et al. Pediatr Rheumatol 2018; 16: 45. doi: 10.1186/s12969-018-0261-x

03-07-2018 | Vasculitis | Article

Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: A retrospective observational study

Bae S, Charles-Schoeman C. Clin Rheumatol 2018; 37: 2113–2123. doi: 10.1007/s10067-018-4174-3

28-06-2018 | Myositis | Review | Article

Update on inclusion body myositis

Jabari D et al. Curr Rheumatol Rep 2018; 20: 52. doi: 10.1007/s11926-018-0755-z

25-06-2018 | Dermatomyositis | Article

Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria

Hinze CH et al. Pediatr Rheumatol 2018; 16: 40. doi: 10.1186/s12969-018-0257-6

20-06-2018 | Dermatomyositis | Article

Current management of juvenile dermatomyositis in Germany and Austria: An online survey of pediatric rheumatologists and pediatric neurologists

Hinze CH et al. Pediatr Rheumatol 2018; 16: 38. doi: 10.1186/s12969-018-0256-7

12-06-2018 | Dermatomyositis | Article

Introduction of a novel magnetic resonance imaging-based scoring system for assessing disease activity in children with juvenile dermatomyositis

Thyoka M et al. Rheumatology (Oxford) 2018: key144. doi: 10.1093/rheumatology/key144

26-05-2018 | Systemic sclerosis | Article

Vascular complications in systemic sclerosis: A prospective cohort study

Mecoli CA et al. Clin Rheumatol 2018. doi: 10.1007/s10067-018-4148-5

Next Previous
Image Credits